Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a/2b double-blind, randomized, placebo-controlled, parallel-group study of VBI-2601 (BRII-179) in non-cirrhotic chronic HBV patients

Next Previous
Trial Profile

Phase 2a/2b double-blind, randomized, placebo-controlled, parallel-group study of VBI-2601 (BRII-179) in non-cirrhotic chronic HBV patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBI 2601 (Primary) ; Peginterferon alfa
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Brii Biosciences

Most Recent Events

  • 22 Mar 2024 According to a Brii Biosciences media release, company will present data on patients meeting NRTI discontinuation criteria from its ongoing Phase 2 study of BRII-179 in combination with PEG-IFN-alpha in CHB patients as an oral late-breaking presentation at the 33rd Conference of Asian Pacific Association for the Study of the Liver (APASL 2024), being held from March 27-31, 2024 in Kyoto, Japan.
  • 14 Nov 2023 Interim results (n=114) week 24/36 data presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 06 Sep 2023 Cohort level unblinded results at week 24 and week 36 presented in the Brii Biosciences Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top